Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB0026 in Healthy Preterm and Term Infants (Phase Ib/II RSV Prevention Trial)
ChiCTR2600129147Phase 2Completed
- Sponsor
- Chengdu Women's and Children's Central Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RB0026 in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Chengdu Women's and Children's Central Hospital. Primary endpoints: Incidence of AE/SAE and AESI during the study period, Incidence of abnormalities in physical examination, vital signs, and laboratory tests versus pre-administration and 1 more. Started Jul 2026; status: completed.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on ChiCTR2600129147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129147.